Hyperhidrosis is a condition characterized by abnormally increased sweating, in excess of that required for regulation of body temperature. Although primarily a physical burden, hyperhidrosis can deteriorate quality of life from a psychological, emotional, and social perspective. It has been called by some 'the silent handicap'.
In 2018, the global Hyperhidrosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Hyperhidrosis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hyperhidrosis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Allergan
GlaxoSmithKline
Revance Therapeutics
Ulthera, Inc
TheraVida
Dermira, Inc
Sientra Inc
...

Market segment by Type, the product can be split into
Medications
Surgical Treatments
Physiotherapy
Others

Market segment by Application, split into
Hospitals
Dermatology Clinics
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Hyperhidrosis Treatment status, future forecast, growth opportunity, key market and key players.
To present the Hyperhidrosis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Hyperhidrosis Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.